Fiji
Diabetes country report 2000 — 2050
Skip Map
Number of adults (20–79 years) with diabetes in Fiji (FJ)
| 2000 | 42.3 thousand |
| 2011 | 55.4 thousand |
| 2024 | 90.3 thousand |
| 2050 | 130.6 thousand |
Fiji is one of the 37 countries and territories in the Western Pacific Region.
Data source(s) used for the diabetes estimates in adults:
- WHO STEPS Fiji 2011
2000
2011
2024
2050
Loading...
| Diabetes estimates (20-79 y) | ||||
|---|---|---|---|---|
| People with diabetes, in 1,000s | 42.3 | 55.4 | 90.3 | 130.6 |
| Age-standardised prevalence of diabetes, % | - | 10.9 | 16.6 | 18.7 |
| Proportion of people with undiagnosed diabetes, % | - | - | 47.5 | - |
| People with undiagnosed diabetes, in 1,000s | - | - | 42.9 | - |
| Impaired Fasting Glucose (IFG) | ||||
|---|---|---|---|---|
| People with IFG, in 1,000s | - | - | 77.2 | 107.1 |
| Age-standardised prevalence of IFG, % | - | - | 13.7 | 14.9 |
| Impaired Glucose Tolerance (IGT) | ||||
|---|---|---|---|---|
| People with IGT, in 1,000s | - | 56.4 | 43.1 | 59.6 |
| Age-standardised prevalence of IGT, % | - | 11.0 | 7.8 | 8.4 |
| Mortality attributable to diabetes (20-79 y) | ||||
|---|---|---|---|---|
| Deaths attributable to diabetes | - | 994.0 | 973.8 | - |
| Proportion of diabetes-related deaths in people 20-79 y, % | - | - | 14.0 | - |
| Hyperglycaemia in pregnancy (HIP) (20-49 y) | ||||
|---|---|---|---|---|
| Live births affected by HIP | - | - | - | - |
| Prevalence of gestational diabetes mellitus (GDM), % | - | - | - | - |
| Live births affected by other types of diabetes first detected in pregnancy | - | - | - | - |
| Live births affected by other types of diabetes detected prior to pregnancy | - | - | - | - |
| Diabetes-related health expenditure | ||||
|---|---|---|---|---|
| Total diabetes-related health expenditure, USD million | - | - | 51.0 | 67.4 |
| Total diabetes-related health expenditure, ID million | - | - | 88.5 | 117.1 |
| Diabetes-related health expenditure per person, USD | - | 230.0 | 564.5 | 516.6 |
| Diabetes-related health expenditure per person, ID | - | - | 980.0 | 896.8 |
| Type 1 diabetes estimates in children and adolescents | ||||
|---|---|---|---|---|
| People with type 1 diabetes (all age groups) | - | - | 120.0 | - |
| People with type 1 diabetes (0-19 y) | - | - | 34.8 | - |
| Demographics | ||||
|---|---|---|---|---|
| Total adult population (20-79 y), in 1,000s | 463.0 | 531.7 | 588.8 | 750.9 |
| Population of children and adolescents (0-19 y) | - | - | 333,429.0 | - |
Loading...
| Diabetes estimates (20-79 y) | |
|---|---|
| People with diabetes, in 1,000s | 42.3 |
| Age-standardised prevalence of diabetes, % | - |
| Proportion of people with undiagnosed diabetes, % | - |
| People with undiagnosed diabetes, in 1,000s | - |
| Impaired Fasting Glucose (IFG) | |
|---|---|
| People with IFG, in 1,000s | - |
| Age-standardised prevalence of IFG, % | - |
| Impaired Glucose Tolerance (IGT) | |
|---|---|
| People with IGT, in 1,000s | - |
| Age-standardised prevalence of IGT, % | - |
| Mortality attributable to diabetes (20-79 y) | |
|---|---|
| Deaths attributable to diabetes | - |
| Proportion of diabetes-related deaths in people 20-79 y, % | - |
| Hyperglycaemia in pregnancy (HIP) (20-49 y) | |
|---|---|
| Live births affected by HIP | - |
| Prevalence of gestational diabetes mellitus (GDM), % | - |
| Live births affected by other types of diabetes first detected in pregnancy | - |
| Live births affected by other types of diabetes detected prior to pregnancy | - |
| Diabetes-related health expenditure | |
|---|---|
| Total diabetes-related health expenditure, USD million | - |
| Total diabetes-related health expenditure, ID million | - |
| Diabetes-related health expenditure per person, USD | - |
| Diabetes-related health expenditure per person, ID | - |
| Type 1 diabetes estimates in children and adolescents | |
|---|---|
| People with type 1 diabetes (all age groups) | - |
| People with type 1 diabetes (0-19 y) | - |
| Demographics | |
|---|---|
| Total adult population (20-79 y), in 1,000s | 463.0 |
| Population of children and adolescents (0-19 y) | - |
